Analysts Expect Amyris Inc (AMRS) Will Post Quarterly Sales of $32.21 Million

Share on StockTwits

Wall Street analysts expect Amyris Inc (NASDAQ:AMRS) to report $32.21 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Amyris’ earnings. The lowest sales estimate is $30.02 million and the highest is $34.40 million. Amyris reported sales of $23.00 million during the same quarter last year, which indicates a positive year-over-year growth rate of 40%. The firm is expected to report its next quarterly earnings results on Monday, May 13th.

On average, analysts expect that Amyris will report full-year sales of $237.56 million for the current fiscal year, with estimates ranging from $225.22 million to $249.90 million. For the next fiscal year, analysts forecast that the company will report sales of $329.75 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Amyris.

Amyris (NASDAQ:AMRS) last issued its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.44 by ($1.51). The company had revenue of $19.36 million during the quarter, compared to the consensus estimate of $98.52 million. During the same quarter in the previous year, the business earned $0.61 EPS. The business’s quarterly revenue was down 76.0% compared to the same quarter last year.

A number of equities research analysts recently issued reports on the company. HC Wainwright set a $11.00 price objective on Amyris and gave the stock a “buy” rating in a research report on Tuesday, February 5th. BidaskClub downgraded Amyris from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Finally, Zacks Investment Research upgraded Amyris from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Amyris presently has a consensus rating of “Buy” and an average target price of $8.83.

Several hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its position in shares of Amyris by 8.6% in the third quarter. Bank of New York Mellon Corp now owns 115,388 shares of the biotechnology company’s stock worth $916,000 after buying an additional 9,172 shares in the last quarter. Balasa Dinverno & Foltz LLC raised its position in Amyris by 99.6% during the fourth quarter. Balasa Dinverno & Foltz LLC now owns 23,711 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 11,834 shares in the last quarter. GSA Capital Partners LLP raised its position in Amyris by 18.9% during the fourth quarter. GSA Capital Partners LLP now owns 76,665 shares of the biotechnology company’s stock valued at $256,000 after purchasing an additional 12,200 shares in the last quarter. Wells Fargo & Company MN raised its position in Amyris by 50.6% during the third quarter. Wells Fargo & Company MN now owns 41,903 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 14,075 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Amyris during the fourth quarter valued at about $48,000. Institutional investors own 36.69% of the company’s stock.

Shares of AMRS stock traded up $0.58 on Friday, reaching $3.45. The company’s stock had a trading volume of 6,741,479 shares, compared to its average volume of 3,647,372. Amyris has a 12-month low of $1.87 and a 12-month high of $9.28. The company has a market capitalization of $219.64 million, a PE ratio of -1.36 and a beta of 0.29.

Amyris Company Profile

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Recommended Story: Why is Cost of Capital Important?

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Microsoft  Hits New 12-Month High at $134.93
Microsoft Hits New 12-Month High at $134.93
Kaiser Aluminum Corp.  CFO Neal E. West Sells 750 Shares
Kaiser Aluminum Corp. CFO Neal E. West Sells 750 Shares
Okta Inc  CEO Sells $226,678.05 in Stock
Okta Inc CEO Sells $226,678.05 in Stock
Okta Inc  General Counsel Sells $63,030.05 in Stock
Okta Inc General Counsel Sells $63,030.05 in Stock
ASV Holdings Inc  Short Interest Down 75.2% in May
ASV Holdings Inc Short Interest Down 75.2% in May
Integra Resources  Stock Price Up 4.7%
Integra Resources Stock Price Up 4.7%


© 2006-2019 Ticker Report